Acute Attack Treatment Escalation and Subsequent Relapse Risk in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease
Open Access
- 8 September 2026
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (5) , e218405
Abstract
ObjectivesAcute treatment for myelin oligodendrocyte glycoprotein antibody–associated disease (MOGAD) includes high-dose IV methylprednisolone (IVMP), with escalation to IV immunoglobulin (IVIG) an...Keywords
This publication has 11 references indexed in Scilit:
- Apheresis therapies in MOGAD: a retrospective study of 117 therapeutic interventions in 571 attacksJournal of Neurology, Neurosurgery & Psychiatry, 2024
- Time to Treat First Acute Attack of Myelin Oligodendrocyte Glycoprotein Antibody-Associated DiseaseJAMA Neurology, 2024
- MOG CNS Autoimmunity and MOGADNeurology Neuroimmunology & Neuroinflammation, 2024
- Predictors of a relapsing course in myelin oligodendrocyte glycoprotein antibody-associated diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2024
- Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteriaThe Lancet Neurology, 2023
- Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGADNeurology Neuroimmunology & Neuroinflammation, 2022
- Myelin-oligodendrocyte glycoprotein antibody-associated diseaseThe Lancet Neurology, 2021
- Treatment Approaches for MOG-Ab-Associated Demyelination in ChildrenCurrent Treatment Options in Neurology, 2019
- Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disordersJournal of Neurology, Neurosurgery & Psychiatry, 2017
- B cell epitope spreading: Mechanisms and contribution to autoimmune diseasesImmunology Letters, 2015